Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

Condition(s) studied

Investigational drug(s) / intervention(s)

Tissue collection: Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling

Data collection: Questionnaire on menstrual health and history of hormone treatments for the research purpose

Study summary

Endometriosis is a chronic gynaecological disease characterised by the growth of endometrium outside the uterus. It affects 10% of childbearing age women.

There is no cure for endometriosis. Hormonal treatments should be the first line therapy. The benefit-risk ratio of symptomatic treatment with hormone therapy varies greatly from one woman to another. The pathophysiology of endometriosis and the mechanisms of action of these treatments are still poorly understood. This may be due to the lack of an optimal experimental model for studying the disease.

The aim of this project is to develop a complex ex vivo endometrial model recapitulating the organisation and properties of the human endometrium using innovative tissue bioengineering methods. This model will make it possible to develop a pre-clinical approach that predicts individual response to different types of hormonal treatment in order to optimise therapeutic choices and provide a better understanding of the effects of these treatments.

Eligibility

Primary outcome measure(s)

• Viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering. — through study completion, an average of 18 months
  The viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering will be assessed either by flow cytometry (labelling with propidium iodide or 7-AAD) or by immunofluorescence (with lipophilic carbocyanine dyes). The scientists involved in the project reserve the right to modify these labelling techniques and the markers mentioned, depending on the technical and logistical challenges encountered during the tissue bioengineering stages.

Trial sites (2)

More Hospices Civils de Lyon trials in France

Other trials for the same condition